MA40765B1 - Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine - Google Patents

Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine

Info

Publication number
MA40765B1
MA40765B1 MA40765A MA40765A MA40765B1 MA 40765 B1 MA40765 B1 MA 40765B1 MA 40765 A MA40765 A MA 40765A MA 40765 A MA40765 A MA 40765A MA 40765 B1 MA40765 B1 MA 40765B1
Authority
MA
Morocco
Prior art keywords
immunity against
protective immunity
methods
immunodeficiency virus
human immunodeficiency
Prior art date
Application number
MA40765A
Other languages
English (en)
Other versions
MA40765A (fr
Inventor
Dan Barouch
Johanna Schuitemaker
Maria Grazia Pau
Manen Danielle Van
Frank Tomaka
Jennifer Hendriks
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc, Janssen Vaccines & Prevention Bv filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of MA40765A publication Critical patent/MA40765A/fr
Publication of MA40765B1 publication Critical patent/MA40765B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions, des vaccins et des méthodes permettant d'induire une immunité protectrice vis-à-vis de l'infection à vih (virus de l'immunodéficience humaine). Des associations de vaccins hétérologues d'un ou plusieurs vecteurs d'expression virale et un polypeptide antigénique isolé induisent une forte immunité protectrice vis-à-vis d'infections par un ou plusieurs clades du vih.
MA40765A 2014-09-26 2015-09-24 Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine MA40765B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056059P 2014-09-26 2014-09-26
PCT/US2015/051891 WO2016049287A1 (fr) 2014-09-26 2015-09-24 Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine

Publications (2)

Publication Number Publication Date
MA40765A MA40765A (fr) 2017-08-02
MA40765B1 true MA40765B1 (fr) 2021-04-30

Family

ID=55581992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40765A MA40765B1 (fr) 2014-09-26 2015-09-24 Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine

Country Status (29)

Country Link
US (4) US10137191B2 (fr)
EP (2) EP3197489B1 (fr)
JP (2) JP6438575B2 (fr)
KR (2) KR101971808B1 (fr)
CN (2) CN112121160A (fr)
AP (1) AP2017009846A0 (fr)
AU (2) AU2015320574B2 (fr)
BR (1) BR112017005917A2 (fr)
CA (1) CA2961024A1 (fr)
CY (1) CY1124254T1 (fr)
DK (1) DK3197489T3 (fr)
EA (2) EA037583B1 (fr)
ES (1) ES2865150T3 (fr)
HR (1) HRP20210608T1 (fr)
HU (1) HUE053585T2 (fr)
IL (2) IL251114B (fr)
LT (1) LT3197489T (fr)
MA (1) MA40765B1 (fr)
MX (2) MX377967B (fr)
MY (1) MY175620A (fr)
PH (1) PH12017500449B1 (fr)
PL (1) PL3197489T3 (fr)
PT (1) PT3197489T (fr)
RS (1) RS61902B1 (fr)
SG (1) SG11201702110RA (fr)
SI (1) SI3197489T1 (fr)
SM (1) SMT202100244T1 (fr)
WO (1) WO2016049287A1 (fr)
ZA (1) ZA201702053B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
AU2017221379A1 (en) * 2016-02-16 2018-08-16 Geovax Inc. Multivalent HIV vaccine boost compositions and methods of use
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
CA3035759A1 (fr) * 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral
AR109528A1 (es) 2016-09-15 2018-12-19 Janssen Vaccines & Prevention Bv Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
CN110958887B (zh) * 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
AU2018304502B2 (en) 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
US20190022212A1 (en) 2017-07-21 2019-01-24 Beth Israel Deaconess Medical Center, Inc. Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en) * 2017-09-18 2019-03-21 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2020064621A1 (fr) 2018-09-25 2020-04-02 Janssen Vaccines & Prevention B.V. Méthode d'induction d'une réponse immunitaire contre le virus de l'immunodéficience humaine par administration co-localisée de composants vaccinaux
CN114269363A (zh) * 2019-04-17 2022-04-01 威斯达研究所 用于hiv疫苗应用的复制缺陷型腺病毒载体
EP3972642A1 (fr) * 2019-05-22 2022-03-30 Aelix Therapeutics S.L. Régimes posologiques pour vaccins
TW202110476A (zh) * 2019-05-22 2021-03-16 荷蘭商傑森疫苗防護公司 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
JP7170942B1 (ja) * 2019-11-07 2022-11-14 ヤンセン ファッシンズ アンド プリベンション ベーフェー タンパク質精製
EP4277652A1 (fr) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Vaccins contre le vih et méthodes d'utilisation
WO2023198815A1 (fr) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Administration séquentielle d'adénovirus

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5298416A (en) 1989-01-18 1994-03-29 British Technology Group Ltd. Attenuated polioviruses
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
WO1998010087A1 (fr) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Vecteurs d'adenovirus de chimpanze
GB0023203D0 (en) 2000-09-21 2000-11-01 Isis Innovation Vaccination method
ATE519855T1 (de) 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001019958A2 (fr) 1999-09-17 2001-03-22 Dana-Farber Cancer Institute, Inc. Trimeres stabilises solubles de glycoproteines
PL212047B1 (pl) 2000-11-23 2012-08-31 Bavarian Nordic As Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
EP2292772A1 (fr) 2001-07-05 2011-03-09 Novartis Vaccines and Diagnostics, Inc. Vaccination VIH avec un ADN codant un polypeptide VIH et un polypeptide VIH
EP2345665A3 (fr) 2001-12-04 2012-02-15 Bavarian Nordic A/S Le vaccin de sous-unité de NS1 de Flavivirus
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
WO2004044155A2 (fr) 2002-11-07 2004-05-27 Beth Israel Deaconess Medical Center Mip-1$g(a) et gm-csf adjuvants de la reponse immune
ES2416629T3 (es) 2002-12-03 2013-08-02 University Of Massachusetts Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación
AU2004226345B2 (en) 2003-03-28 2011-12-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVA virus expressing modified HIV envelope, gag, and pol genes
US20070166784A1 (en) * 2003-09-15 2007-07-19 Barnett Susan W Combination approaches for generating immune responses
US20070298051A1 (en) 2003-11-19 2007-12-27 Beth Israel Deaconess Medical Center Adjuvants Of Immune Response
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20080274134A1 (en) 2004-06-15 2008-11-06 Norbert Schulke Hiv-1 Neutralizing Antibodies Elicited By Trimeric Hiv-1 Envelope Glycoprotein Complex
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
US9453239B2 (en) 2004-08-27 2016-09-27 Emory University Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes
BRPI0516048A (pt) 2004-10-13 2008-08-19 Crucell Holland B V E Beth Isr batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c
WO2006050394A2 (fr) * 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Approches combinatoires destinees a produire des reponses immunitaires
WO2007005934A2 (fr) 2005-07-06 2007-01-11 University Of Maryland Biotechnology Institute Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur
CN101969996A (zh) 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
CA2655934A1 (fr) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Proteines env vih trimeriques solubles stabilisees et leurs utilisations
WO2008063331A2 (fr) 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci
WO2008140579A2 (fr) 2006-11-17 2008-11-20 New York University Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
WO2010059732A1 (fr) 2008-11-18 2010-05-27 Beth Israel Deaconess Medical Center Vaccins antiviraux présentant une immunogénicité cellulaire améliorée
EP2391638B1 (fr) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Séquences d'acide aminé et d'acide nucléique d'adénovirus simien, vecteurs les contenant, et utilisations afférentes
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
WO2010096561A1 (fr) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéines gag du vih/vis de synthèse et leurs utilisations
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
WO2011092029A1 (fr) 2010-01-28 2011-08-04 Bavarian Nordic A/S Mutants du virus de la vaccine comportant les principales délétions génomiques du virus de la vaccine ankara modifiée
MX2012007936A (es) * 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
CA3249351A1 (fr) 2010-08-31 2025-07-03 Theraclone Sciences, Inc. Anticorps neutralisants anti-virus de l'immunodéficience humaine (vih)
WO2012048817A2 (fr) 2010-10-15 2012-04-19 Bavarian Nordic A/S Vaccin contre la grippe à base d'un virus de la vaccine ankara recombinant, modifié
DK2655604T3 (en) * 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
WO2013036791A2 (fr) 2011-09-09 2013-03-14 Beth Israel Deaconess Medical Center, Inc. Vecteurs adénoviraux modifiés et procédés de traitement dans lesquels ils interviennent
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
EP2766037A4 (fr) 2011-10-12 2015-08-05 Scripps Research Inst Mini boucle v3 de gp120 du vih-1 et ses utilisations
US9683268B2 (en) 2012-09-19 2017-06-20 Beth Israel Deaconess Viruses associated with immunodeficiency and enteropathy and methods using same
EP4631509A3 (fr) 2012-11-16 2026-03-04 Beth Israel Deaconess Medical Center, Inc. Adénovirus recombinants et leur utilisation
AP2015008634A0 (en) * 2013-01-07 2015-07-31 Beth Israel Hospital Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
EP3052132B1 (fr) 2013-09-30 2020-07-29 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
CN103992396B (zh) * 2014-04-17 2017-03-29 南开大学 一种潜在的高效重组HIV‑1 CRF07‑BC gp140免疫原的制备方法
WO2016037154A1 (fr) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation
ES2865150T3 (es) * 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
PT3390430T (pt) 2015-12-15 2019-11-20 Janssen Vaccines & Prevention Bv Antígenos, vetores, composições para o vírus da imunodeficiência humana e métodos da sua utilização
CA3035759A1 (fr) * 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral

Also Published As

Publication number Publication date
MY175620A (en) 2020-07-02
ZA201702053B (en) 2021-09-29
US20160089432A1 (en) 2016-03-31
SG11201702110RA (en) 2017-04-27
EP3868398A1 (fr) 2021-08-25
IL251114A0 (en) 2017-04-30
PH12017500449A1 (en) 2017-07-31
PH12017500449B1 (en) 2022-07-22
KR20170066454A (ko) 2017-06-14
SI3197489T1 (sl) 2021-08-31
EA202092521A1 (ru) 2021-05-31
HRP20210608T1 (hr) 2021-06-11
AU2018267669B2 (en) 2020-03-05
IL251114B (en) 2019-05-30
ES2865150T3 (es) 2021-10-15
AU2018267669A1 (en) 2018-12-13
MX377967B (es) 2025-03-10
EP3197489A4 (fr) 2018-03-14
US20180250385A1 (en) 2018-09-06
US10137191B2 (en) 2018-11-27
BR112017005917A2 (pt) 2017-12-12
JP6438575B2 (ja) 2018-12-12
EA037583B1 (ru) 2021-04-16
RS61902B1 (sr) 2021-06-30
HUE053585T2 (hu) 2021-07-28
CY1124254T1 (el) 2022-07-22
US20220096622A1 (en) 2022-03-31
AU2015320574B2 (en) 2018-12-06
KR20190042736A (ko) 2019-04-24
CN106999571A (zh) 2017-08-01
AP2017009846A0 (en) 2017-03-31
IL265733B (en) 2021-05-31
SMT202100244T1 (it) 2021-07-12
DK3197489T3 (da) 2021-04-19
MA40765A (fr) 2017-08-02
EA201790717A1 (ru) 2018-02-28
IL265733A (en) 2019-05-30
PL3197489T3 (pl) 2021-11-08
CN112121160A (zh) 2020-12-25
US20200030437A1 (en) 2020-01-30
JP2017531627A (ja) 2017-10-26
EP3197489A1 (fr) 2017-08-02
JP6625716B2 (ja) 2019-12-25
PT3197489T (pt) 2021-04-30
CN106999571B (zh) 2020-10-02
MX2020013153A (es) 2021-02-18
CA2961024A1 (fr) 2016-03-31
KR102159626B1 (ko) 2020-09-25
JP2019038849A (ja) 2019-03-14
NZ730841A (en) 2021-08-27
AU2015320574A1 (en) 2017-04-06
EP3197489B1 (fr) 2021-02-17
US11207400B2 (en) 2021-12-28
WO2016049287A1 (fr) 2016-03-31
KR101971808B1 (ko) 2019-04-23
LT3197489T (lt) 2021-07-26
MX2017003946A (es) 2017-12-20
US10471137B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
MA40765B1 (fr) Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
EA202092808A1 (ru) Вакцины на основе наночастиц с новыми структурными компонентами
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
EP4691484A3 (fr) Vaccins contre l'arnm de la grippe
EA201790532A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
WO2015134368A3 (fr) Vecteurs de vaccin du virus de l'herpès simplex 2 (vhs -2) de recombinaison(hsv -2)
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
CO2018008288A2 (es) Virus de la tilapia de tipo ortomixo
MX2018013340A (es) Combinaciones de vacunas terapeuticas para el vph.
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
EA201990719A1 (ru) Новые промоторы
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
EA202191862A3 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
PH12017502378A1 (en) Inactivated canine influenza vaccines and methods of making and uses thereof